NextPoint Therapeutics

Executive Summary

NextPoint Therapeutics is a preclinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics targeting the HHLA2 pathway, a novel immune checkpoint distinct from PD-1/PD-L1. The company's lead candidate, NPX267, is a first-in-class inhibitory antibody designed to block HHLA2-mediated immunosuppression, with the goal of restoring antitumor immunity in solid tumors. Backed by $122.5 million in total funding, NextPoint is poised to advance NPX267 into clinical development. The HHLA2 pathway offers a promising alternative for patients who do not respond to current checkpoint inhibitors, and NextPoint's differentiated approach could address a large unmet need across multiple cancer types. However, the company remains at a preclinical stage, with no clinical data yet generated. Success hinges on successful IND filing and initial safety/tolerability data from Phase 1 trials.

Upcoming Catalysts (preview)

• H2 2026IND Filing for NPX26770% success
• H1 2027Phase 1 Trial Initiation60% success
• Q4 2026Preclinical Data Presentation at Major Conference (e.g., SITC 2026)80% success